Black Diamond Therapeutics (BDTX) Net Cash Flow (2019 - 2026)

Black Diamond Therapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at $9.1 million for Q1 2026.

• Quarterly Net Cash Flow fell 85.35% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.3 million (down 193.62% YoY) and the FY2025 annual result came in at -$15.4 million, up 21.99% from the prior year.
• Net Cash Flow was $9.1 million for Q1 2026 at Black Diamond Therapeutics, up from -$9.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $62.0 million in Q1 2025 and bottomed at -$68.4 million in Q2 2025.
• A 5-year average of -$2.1 million and a median of $874000.0 in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow surged 918.0% — and 2025, when it slumped 1025.7%.
• Black Diamond Therapeutics' Net Cash Flow stood at -$19.6 million in 2022, then soared by 91.08% to -$1.8 million in 2023, then surged by 841.87% to $13.0 million in 2024, then tumbled by 175.91% to -$9.9 million in 2025, then surged by 192.01% to $9.1 million in 2026.
• Business Quant data shows BDTX's Net Cash Flow at $9.1 million in Q1 2026, -$9.9 million in Q4 2025, and $874000.0 in Q3 2025.